InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of people with methamphetamine overdose and methamphetamine use disorder. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and has demonstrated positive Phase 2 clinical proof-of-concept data (STAMPOUT; NCT03336866). We are currently evaluating IXT-m200 in a Phase 2 study for methamphetamine overdose (Meth-OD), and we are planning another Phase 2 study of IXT-m200 in people with methamphetamine use disorder (OUTLAST).